Matribhumi Samachar English
Montreal, Quebec–(Newsfile Corp. – December 10, 2025) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (“Defence” or the “Company”), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce that the Shareholders approved …
Read More »Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
Montreal, Quebec–(Newsfile Corp. – December 4, 2025) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (“Defence” or the “Company”), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce the formation of its …
Read More »Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology
Montreal, Quebec–(Newsfile Corp. – June 9, 2025) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company“), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its U.S. …
Read More »Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub
Montreal, Quebec–(Newsfile Corp. – June 2, 2025) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a leading biotechnology company specializing in advanced endosomal escape technologies, is pleased to announce the opening of its first U.S. laboratory in the Boston-Cambridge area. This strategic expansion marks Defence …
Read More »Defence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer Therapies
Montreal, Quebec–(Newsfile Corp. – April 8, 2025) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing advanced cancer therapeutics and drug delivery technologies, is pleased to announce a collaboration with the Canadian Nuclear Laboratories (“CNL”). CNL, Canada’s premier nuclear science facility, …
Read More »Defence Announces US Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Defence’s Management Team as Chief Operating Officer
Montreal, Quebec–(Newsfile Corp. – March 26, 2025) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that Dr. …
Read More »Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million
Montreal, Quebec–(Newsfile Corp. – January 31, 2025) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce the closing …
Read More »